SCHEMBL2215071

SCHEMBL2215071

CS(=O)(=O)c1nc(-c2ccc3cc(OCc4ccccc4)ccc3c2)cc2ccnn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.42
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 2/20 0.40
MCL1 Q07820 2/20 0.40
XDH P47989 1/20 0.40
ENPP3 O14638 1/20 0.39
ENPP1 P22413 1/20 0.39
SRC P12931 2/20 0.38
ABL1 P00519 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
MAOA P21397 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213852 0.82 ALOX5 (0.44) ALOX5NPC1RAB9AMEN1KMT2A
SCHEMBL2214081 0.79 SCD (0.42) RAB9AMEN1KMT2ACYP3A4CA12
SCHEMBL2216217 0.72 ALOX5 (0.45) ALOX5NPC1RAB9AMEN1KMT2A
SCHEMBL30069959 0.72 ALOX5 (0.56) ALOX5NPC1RAB9AMEN1KMT2A
SCHEMBL2876715 0.72 PLCG1 (0.43) NPC1RAB9AMEN1KMT2AMCL1
SCHEMBL2213749 0.70 NPC1 (0.44) NPC1RAB9AMEN1KMT2AHPGD
SCHEMBL30070008 0.66 ALOX5 (0.51) ALOX5NPC1RAB9AMEN1KMT2A
SCHEMBL5906786 0.66 EGFR (0.53) NPC1RAB9AMEN1KMT2ACYP3A4
SCHEMBL8615408 0.64 ALOX5 (0.55) ALOX5NPC1RAB9AMEN1KMT2A
SCHEMBL4506543 0.64 CYP11B2 (0.68) ALOX5CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 ALOX5 3694/4885NPC1 3449/4885RAB9A 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.